The Opioid Reckoning (Part 1): Paul Farrell Jr.

The Opioid Reckoning (Part 1): Paul Farrell Jr. on Litigation, Accountability, and the System That Failed

West Virginia has had the highest drug overdose death rate in the United States for over a decade. In a state with fewer than 2 million people, 780 million prescription opioids were distributed in just six years.

For Paul Farrell Jr., a Huntington, West Virginia native and mass tort attorney, those numbers weren’t abstract statistics. They were neighbors. Friends. Family members.

In Part 1 of this two-part episode, hosts Na-Ri Oh and Ian Wendt sit down with Paul to unpack how the largest civil litigation in American history — the opioid multidistrict litigation (MDL 2804) — came together, and how it reshaped the conversation around corporate accountability in the pharmaceutical supply chain.

This is not just a legal story. It’s a story about systems failure — across manufacturers, distributors, regulators, policymakers, and healthcare stakeholders — and what happens when transparency finally forces a reckoning.

In This Episode

• Growing up in Huntington, WV as the opioid crisis escalated

• The investigative journalism that exposed 780 million pills — and the moment Paul decided to act

• What “public nuisance” law is — and why it became the legal breakthrough strategy

• The role of distributors as the “choke point” in the opioid supply chain

• How 3,000+ cases consolidated into the largest MDL in U.S. history

• Why abatement — not just financial damages — became central to the settlement strategy

• Internal company communications that revealed troubling attitudes toward affected communities

• The intersection of regulation, enforcement, and corporate responsibility

• How transparency and subpoena power changed the trajectory of the crisis

Why This Conversation Matters

For those working in pharma, healthcare, commercialization, policy, compliance, or distribution, this episode challenges us to examine difficult questions:

• Where does responsibility truly lie in a complex healthcare ecosystem?

• What happens when financial incentives distort oversight?

• And how do we prevent the next Pandora’s box from opening?

This episode sets the foundation for a deeper conversation about accountability, culture, regulation, and reform.

Coming Next Week: Part 2

There was simply too much to cover in one episode.

In Part 2, we’ll explore:

• The evolution of the litigation and key tipping points

• The role of state attorneys general and settlement frameworks

• The ongoing PBM litigation

• The documentary The Bitter Pill

• And what lasting change should look like for the industry

Make sure to subscribe so you don’t miss it.